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a  b  s  t  r  a  c  t
Although  cognitive  and  behavioral  therapies  are  effective  in  the treatment  of  anxiety  disorders,  it is not
clear  what  the  relative  effects  of these  treatments  are. We  conducted  a meta-analysis  of  trials  comparing
cognitive  and behavioral  therapies  with  a control  condition,  in  patients  with  social  anxiety  disorder
(SAD),  generalized  anxiety  disorder  (GAD)  and  panic  disorder.  We  included  42  studies  in  which  generic





disorder as  measured  on the  BAI  (13.33  points;  95%  CI: 10.58–16.07)  were  significantly  (p  =  0.001)  larger
than  the  effect  sizes  on  GAD  (6.06  points;  95%  CI:  3.96–8.16)  and  SAD  (5.92  points;  95%  CI: 4.64–7.20).
The  effects  remained  significant  after  adjusting  for  baseline  severity  and other  major  characteristics  of
the trials.  The  results  should  be considered  with  caution  because  of  the  small  number  of studies  in many
subgroups  and  the  high  risk  of bias  in most  studies.
©  2016  Published  by  Elsevier  Ltd.ontents
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. Introduction
It is well-established that cognitive and behavioral therapies
re effective in the treatment of anxiety disorders, including social
nxiety disorder (Acarturk, Cuijpers, van Straten, & de Graaf, 2009;
skildsen, Hougaard, & Rosenberg, 2010), generalized anxiety dis-
rder (Cuijpers, Sijbrandij et al., 2014; Hunot, Churchill, Silva de
ima, & Teixeira, 2007) and panic disorder (Sánchez-Meca, Rosa-
lcázar, Marín-Martínez, & Gómez-Conesa, 2010). Although some
ther types of treatment have been developed for the treatment of
nxiety disorders, like psychodynamic (Leichsenring et al., 2009;
ilrod et al., 2007) and interpersonal psychotherapies (Dagöö et al.,
014; Lipsitz et al., 2008; Vos, Huibers, Diels, & Arntz, 2012), cog-
itive and behavioral therapies have been examined in dozens of
andomized trials and have been consistently shown to be effective
n the treatment of anxiety disorders with large effect sizes across
isorders.
It is not clear, however, what are the relative effects of the
reatment of one anxiety disorder compared to another. Most out-
ome instruments are specifically designed to measure the effects
f each disorder separately. For example many studies examin-
ng the effects of treatments of social anxiety disorder use the
iebowitz Social Anxiety Scale (Baker, Heinrichs, Kim, & Hofmann,
002; Liebowitz, 1987) as outcome measure, but many studies on
eneralized anxiety disorder use the Penn State Worry Question-
aire (Meyer, Miller, Metzger, & Borkovec, 1990), while studies on
anic disorder use the frequency of panic attacks as main outcome
easure. This makes it impossible to compare the relative effects of
ognitive and behavioral treatments in different anxiety disorders.
The relative effects of treatments for different anxiety disorders
re, however, important for several reasons. Firstly, how well a dis-
rder can be treated is important from a public health perspective
GBD 2013 DALYs and HALE Collaborators et al., 2015). If a disorder
an be treated effectively it is less important to develop new treat-
ents that could potentially be better than existing ones since the
isease burden of this disorder can be ameliorated with existing
reatments. If a disorder cannot be treated effectively, it is more
mportant to develop new or improved therapies. Understanding
he relative effectiveness of a treatment is also important for clin-
cians and patients when deciding whether and how to treat the
isorder. From a scientific perspective, differences in effectiveness
ay  be helpful in understanding the underlying processes that lead
o these disorders and in explaining how treatments work.
The relative effects of cognitive and behavioral treatments
etween various anxiety disorders can be assessed in meta-
nalyses, which delineate the relative effects by giving estimates
n terms of effect sizes (standardized mean difference). However,
hese effect sizes are still statistical concepts, indicating the differ-
nce between a treatment and control group in terms of standard
eviations, and do not say anything about the clinical effect of a
reatment (Cuijpers, Turner, Koole, van Dijke, & Smit, 2014). For
xample, an effect size of d = 0.1 on mortality would by most clini-
ians and patients be considered a highly clinically important effect,
hile an effect of d = 0.1 on social skills would not be considered be
elevant by most. This implies that effect sizes cannot be directly
ompared across disorders, because from a clinical perspective an . . .  . .  . . . . .  . . . .  . . . .  . . .  . . .  . . .  .  .  . . .  . . . .  .  . . . . . . .  . . . . .  .  . . .  . . . . . .  .  . .  .  .  .  .  . . . .  . . .  . . . 87
effect size in one disorder may  have different implications than that
same effect size in another disorder.
However, in the field of anxiety there are several outcome
instruments that measure general levels of anxiety and that are
not related to specific anxiety disorders, such as the Beck Anxiety
Inventory (BAI; Beck, Epstein, Brown, & Steer, 1988)), the Hamilton
Rating Scale for Anxiety (HAMA; Hamilton (1959)), and the State-
Trait Anxiety Inventory (STAI-S tate and STAI-Trait; Spielberger,
Gorsuch, Lushene, Vagg, & Jacobs, 1983). These instruments may
not fully capture the specific effects of treatments on a specific dis-
order, because they measure anxiety in general, and not the specific
symptoms of particular anxiety disorders. However, they can give
an indication about the relative effects of treatments across disor-
ders because they give a generic assessment of anxiety, not attached
to a specific anxiety disorder. Effect sizes based on these mea-
sures can be considered comparable across disorders, because they
use exactly the same instrument, in contrast to disorder-specific
outcomes whose effect sizes cannot be compared directly. These
outcome instruments are used in a considerable number of trials
on cognitive and behavioral therapies for anxiety disorders.
We decided to conduct a meta-analysis of trials including instru-
ments that measure general anxiety symptoms in order to make
a comparison between the outcomes of cognitive and behavioral
therapies in three of the most common anxiety disorders: panic
disorder, social anxiety disorder, and generalized anxiety disorder.
We focused on these three disorders because these are among the
most important and common anxiety disorders in adults according
to the DSM-5 (American Psychiatric Association, 2013).
2. Methods
2.1. Identification and selection of studies
We  searched four major bibliographical databases (PubMed,
PsycInfo, Embase and the Cochrane Database of randomized trials)
by combining terms (both MeSH terms and text words) indicative of
social anxiety disorder (such as social phobia, social anxiety, public-
speaking anxiety), generalized anxiety disorder (such as worry and
generalized anxiety), and panic (such as panic, panic disorder), with
filters for randomized controlled trials. We  also checked the refer-
ences of earlier meta-analyses of psychological treatments for the
included disorders. The exact search string for PubMed is given in
Appendix A. The deadline for the searches was  August 14, 2015.
We included (a) randomized trials (b) in which the effects of
a cognitive or behavioral treatment (c) on anxiety measured with
the BAI, HAMA, STAI-Trait and/or STAI-State (d) was directly com-
pared with a control group (waiting list, care-as-usual, placebo
or other) (e) in adults (f) with a panic disorder (with or without
agoraphobia), generalized anxiety disorder (GAD), or social anxi-
ety disorder (SAD). Only studies in which subjects met diagnostic
criteria for the disorder according to a structured diagnostic inter-
view (such as the SCID, CIDI, or MINI) were included. We  choose
the BAI, HAMA and STAI for inclusion because these are by far the
most used generic measures of anxiety in outcome studies. Cog-
nitive and behavioral therapies were defined as therapies aimed
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or. Studies on EMDR, interpersonal and psychodynamic therapy
ere excluded, because they are not considered to be cognitive
ehavior therapy, and don’t offer the cognitive and behavioral
trategies that are typically offered in CBT. We  also excluded stud-
es in which (applied) relaxation was examined as a stand-alone
reatment, because relaxation is effective in GAD, but less so for
xample in panic disorder (Siev & Chambless, 2007) and may  there-
ore affect pooled outcomes across disorders. Comorbid mental or
omatic disorders were not used as an exclusion criterion. Stud-
es on inpatients, adolescents and children (below 18 years of age)
ere excluded. We  also excluded maintenance studies, aimed at
eople who had already recovered or partly recovered after an ear-
ier treatment, and studies that did not report sufficient data to
alculate standardized effect sizes. Studies in English, German, and
utch were considered for inclusion.
.2. Quality assessment and data extraction
We  assessed the validity of included studies using four criteria
f the ‘Risk of bias’ assessment tool, developed by the Cochrane
ollaboration (Higgins & Green, 2011). This tool assesses possible
ources of bias in randomized trials, including the adequate gen-
ration of allocation sequence; the concealment of allocation to
onditions; the prevention of knowledge of the allocated interven-
ion (masking of assessors); and dealing with incomplete outcome
ata (this was assessed as positive when intention-to-treat analy-
es were conducted, meaning that all randomized patients were
ncluded in the analyses). The assessment of the validity of the
ncluded studies was conducted by two independent researchers,
nd disagreements were solved through discussion.
We  also coded participant characteristics (disorder; recruit-
ent method; target group); characteristics of the psychotherapies
treatment format; number of sessions); and general characteris-
ics of the studies (country where the study was  conducted; year
f publication).
.3. Meta-analyses
For each comparison between a psychotherapy and a control
ondition, the effect size indicating the difference between the two
roups at post-test was  calculated (Hedges’s g). Effect sizes were
alculated by subtracting (at post-test) the average score of the psy-
hotherapy group, from the average score of the control group, and
hen dividing this result by the pooled standard deviation. Because
ome studies had relatively small sample sizes we corrected the
ffect size for small sample bias (Hedges & Olkin, 1985). If means
nd standard deviations were not reported, we used the procedures
f the Comprehensive Meta-analysis software (see below) to cal-
ulate the effect size using dichotomous outcomes; and if these
ere not available either, we used other statistics (such a t-value
r p-value) to calculate the effect size. We  also calculated (unstan-
ardized) mean differences that indicate the difference between
reatment and control groups in terms of points on the specific
cale used (the BAI, HAMA, STAI-State, STAI-Trait).
We also calculated effect sizes indicating the improvement
rom baseline to post-test for the treatment groups in the studies.
ecause baseline and post-test values are not independent from
ach other, we assumed a conservative correlation between base-
ine and post-test score of r = 0.70.
Apart from the outcomes of the studies on the BAI, HAMA, STAI-
tate and STAI-Trait, we also collected effect sizes based on disorder
pecific measures from the included trials, such as the PSWQ for
eneralized anxiety disorder, and the LSAS for social anxiety. By col-
ecting these disorder-specific outcomes we could assess whether
he effect sizes based on the BAI, HAMA and STAI (measuring anx-
ety in general) differed from disorder-specific outcomes. We  did Disorders 43 (2016) 79–89 81
not include measures on cognitions or other indirect outcomes or
generic measures of anxiety (other than the BAI, HAMA and STAI).
To calculate pooled mean effect sizes, we used the computer
program Comprehensive Meta-Analysis (version 3.3070; CMA).
Because we expected considerable heterogeneity among the stud-
ies, we employed a random effects pooling model in all analyses
(Borenstein, Hedges, Higgins, & Rothstein, 2009).
In order to assess baseline difference among patients with GAD,
SAD and panic disorder, we  pooled the mean on the BAI, HAMA,
STAI-State and STAI-Trait at baseline using the means, standard
deviations and N of the treatment groups according to the pro-
cedures implemented in CMA. Numbers-needed-to-treated (NNT)
were calculated using the formulae provided by Kraemer and
Kupfer (2006).
As a test of homogeneity of effect sizes, we calculated the I2-
statistic, which is an indicator of heterogeneity in percentages. A
value of 0% indicates no observed heterogeneity, and larger values
indicate increasing heterogeneity, with 25% as low, 50% as moder-
ate, and 75% as high heterogeneity (Higgins, Thompson, Deeks, &
Altman, 2003). We  calculated 95% confidence intervals around I2
(Ioannidis, Patsopoulos, & Evangelou, 2007), using the non-central
chi-squared-based approach within the heterogi module (Orsini,
Bottai, Higgins, & Buchan, 2006) for Stata.
We conducted subgroup analyses according to the mixed effects
model, in which studies within subgroups are pooled with the ran-
dom effects model, while tests for significant differences between
subgroups are conducted with the fixed effects model. For contin-
uous variables, we used meta-regression analyses to test whether
there was a significant relationship between the continuous vari-
able and effect size, as indicated by a Z-value and an associated
p-value. Multivariate metaregression analyses, with the effect size
as the dependent variable, were conducted in CMA.
We  tested for publication bias by inspecting the funnel plot on
primary outcome measures and by Duval and Tweedie’s trim and
fill procedure (Duval & Tweedie, 2000), which yields an estimate of
the effect size after the publication bias has been taken into account
(as implemented in CMA).
3. Results
3.1. Selection and inclusion of studies
After examining a total of 10,368 abstracts (6196 after removal
of duplicates), we  retrieved 1072 full-text papers for further con-
sideration. We  excluded 1031 of the retrieved papers. The PRISMA
flowchart describing the inclusion process, including the reasons
for exclusion, is presented in Fig. 1. A total of 42 studies met
inclusion criteria for this meta-analysis (two of the studies were
described in one paper; Mohlman et al. (2003)), 20 studies on GAD,
12 studies on panic disorder, and 10 on SAD. Selected characteristics
of the included studies are reported in Table 1.
3.2. Characteristics of included studies
In the 42 studies a total of 2477 patients participated (1504 in the
treatment groups and 973 in the control groups). Thirty-three stud-
ies were aimed at adults in general, six were aimed at older adults
and three at other target groups (undergraduate students, unem-
ployed homeless adults and African-American women). Fifteen
studies recruited patients exclusively from clinical populations, 22
recruited (also) from the community, and five used other recruit-
ment methods. The 42 studies included a total of 56 comparisons
between a CBT condition and a control condition. In the 56 CBT
conditions, the treatment was delivered in individual format in 33
studies, in 12 studies it was delivered in group format, in six studies
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Table  1
Selected characteristics of randomized controlled trials examining the effects of cognitive and behavioral treatments of generalized anxiety disorders, panic disorder and
social  anxiety disorder on the BAI, HAMA, STAI-Trait and STAI-State.
Study Disorder Recr Target group Conditions N Format N sess-ions Study Quala C
Abramowitz et al.
(2009)
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Table  1 (Continued)
Study Disorder Recr Target group Conditions N Format N sess-ions Study Quala C




Ind nr − − − − UK










− − + − UK










− − sr − GER





Grp 15 − − + + US




Ind 8 − − − − US










+ − + + US




Ind (tel) 8 − − sr − CAN
van der Heiden et al.
(2012)










+ + + + NL




Grp 12 − − + + US












− − sr − UK




Ind 12 − − + − US
Abbreviations: BR: Brazil; CAN: Canada; CAU: Care as Usual; CBT: Cognitive Behavioral Therapy; Clin: participants recruited in a clinical setting; Comm: participants recruited
in  a community setting; CT: Cognitive Therapy; GAD: Generalized Anxiety Disorder; GER: Germany; Grp: group format; Gsh: guided self-help format; Ind: individual format;
Ind  (tel): individual telephone format; Intol-Uncert ther: Intolerance-of-Uncertainty Therapy; IR: Iran; MDD: Major Depressive Disorder; NL: The Netherlands; Panic: Panic
Disorder; Recr: Recruitment; RT: Relaxation Therapy; SAD: Social Anxiety Disorder; Soc. skills tr.: Social Skills Training; SP: Spain; SW:  Sweden; UK: United Kingdom; US:
United States of America.
a In this column a positive (+) or negative (−) sign is given for four quality criteria of the




References identified  by literat ure search: 
–  Pubmed 75 7 45 7 94 7 2161 
–  Cochran e  1831  1083  1597 4511 
–  PsycInf o 55 8 32 9 48 4 1371 
– Embas e 59 6 81 5 91 4 2325 
86301249348622473latoT
After remova l of  duplicates 226 7  1619  2310 6196 
⇓
Full-text  retri eved 19 6 33 0 54 6 1072 
⇓
Excluded: 
–  Duplicate  papers   36  53  63 152 
– No  di agn osis   44  58 14 7 249 
– No relevant comparison 30 94 180 304 
– No  CB T  22  23  55 100 
– No  BAI,  HAMA,  STA I 29  53  43  125 
– Other  re ason  15  40  46 101 
Total excluded 176 321 534 1031 
⇓
Included  in  meta-a nalys is  20  9  12 41 
a
f
Fig. 1. Flowchart for the inclusion of studies. guided self-help format was utilized, and 5 studies used another
ormat (telephone or mixed). The number of treatment sessions study, respectively: allocation sequence; concealment of allocation to conditions;
n the third criterion indicates that only self-report measures were used (and no
ranged from 3 to 24, with the majority (35 out of 56) having 12
sessions or less. In 31 studies a waiting list control group was  used,
6 used a pill placebo control group, three had a care-as-usual con-
trol group, and two a minimal contact control. Fifteen studies were
conducted in the US, 22 in Europe, four in Canada and one in Brazil.
3.3. Quality assessment
The quality of the studies varied. Ten studies reported an ade-
quate sequence generation, while the other 32 did not. Eight of
the 42 studies reported allocation to conditions by an independent
(third) party. Thirty-three studies reported blinding of outcome
assessors or used only self-report outcomes and 22 studies con-
ducted intention-to-treat analyses (a post-treatment score was
analyzed for every randomized patient even if the last observation
prior to attrition had to be carried forward or that score was esti-
mated from earlier response trajectories). Eleven studies met  three
or four quality criteria, another 8 studies met  two criteria, and the
remaining 23 studies met  one or none of the criteria.
3.4. Baseline differences among patients in treatments on GAD,
SAD and panic disorders
We first examined whether the baseline scores on the BAI,
HAMA, STAI-Trait and STAI-State differed among patients with
GAD, SAD and panic disorder. The pooled means are reported in
Table 2. As can be seen, the baseline scores of the three disorders
differed significantly for all outcome measures, except for the BAI
(although there was a trend of p < 0.1 suggesting a possible signif-
icant difference). However, the number of studies was  very small
in some subgroups. Heterogeneity was very high in most analyses
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Table  2
Pooled mean baseline scores on general measures of anxiety in patients participating in cognitive and behavioral therapies for GAD, SAD and panic disorder.a
Ncomp Mean 95% CI I2 95% CI pb
Beck Anxiety Inventory
–Generalized anxiety disorder 8 20.17 18.37–21.98 83 64–90 0.08
–Social  anxiety disorder 8 17.79 15.18–20.41 76 43–86
–Panic  disorder 4 23.38 19.07–27.68 78 0–90
Hamilton
–Generalized anxiety disorder 11 19.02 17.25–20.78 88 80–92 ≤0.001
–Social anxiety disorder 2 15.85 14.30–17.40 0 c
–Panic disorder 10 20.66 19.48–21.83 58 0–78
STAI-state
–Generalized anxiety disorder 5 55.60 51.03–60.17 84 55–91 ≤0.001
–Social anxiety disorder 3 35.09 31.47–38.71 0 0–73
–Panic  disorder 2 46.45 42.63–50.26 0 c
STAI-trait
–Generalized anxiety disorder 16 54.46 51.75–57.169 92 89–94 0.02
–Social anxiety disorder 2 51.29 39.88–62.70 86 c
–Panic disorder 5 49.41 47.33–51.48 0 0–64







































a According to the random effects model.
b The p-values in this column indicate whether the difference between the effect
c The 95% CI of I2 cannot be calculated when the number of studies is two or sma
ith larger samples of studies, as is typically the case when pool-
ng absolute numbers (Higgins & Green, 2011). However, because
f these baseline differences we decided to add baseline scores in
he multivariate analyses examining whether the effect sizes of the
herapies differed across disorders (see below).
.5. Differential outcomes on anxiety of trials across GAD, SAD
nd panic disorders
The differential outcomes of the treatments for the three dis-
rders on the BAI, HAMA, STAI-Trait and STAI-State are reported
n Table 3. We  only found significant differences across disorders
or the BAI, but not for the HAMA, STAI-Trait and STAI-State. How-
ver, the number of comparisons in several of the subgroups was
mall, so the lack of significant relative effects may  be related to
ow statistical power.
For the BAI, we found that the effects of treatments on panic dis-
rder were considerably larger than for GAD and SAD (p < 0.001).
he effect sizes for the BAI for all included studies, grouped accord-
ng to disorder, are presented in Fig. 2. Pairwise comparison showed
hat the difference between GAD and panic (p < 0.001) and between
AD and panic (p < 0.1) were significant, but the difference between
AD and SAD was not significant (p > 0.1). The difference between
he treatment and control groups at post-test was 13.33 points (95%
I: 10.58–16.07) on the BAI for panic disorder, 6.06 points (95% CI:
.96–8.16) points for GAD, and 5.92 points (95% CI: 4.64–7.20) for
AD. The NNTs were 1.42, 2.54 and 2.54 respectively.
Because the BAI was the most used instrument across disor-
ers, we examined potential publication bias in the studies using
he BAI. For GAD we found that adjustment for publication bias
esulted in a decrease of the effect size from g = 0.67 to g = 0.66
95% CI: 0.48–0.84; number of missing studies: 1). For panic we
ound that the effect size decreased from g = 1.48 to g = 1.40 (95%
I: 1.07–1.72; number of missing studies: 1). For SAD we found no
ndication for publication bias (unadjusted and adjusted effect sizes
ere identical with no missing studies).
.6. Improvement from baseline to post-test
Because the baseline scores for the BAI, HAMA, STAI-Trait and
TAI-State differed at baseline for the disorders, we also calculated
he effect sizes indicating the improvement from baseline to post-
est within the treatment groups (Table 4). As can be seen from
he Table, the results are very much in line with the findings forin the subgroups is significant.
the effect sizes indicating the difference between the treatment
and control group at post-test. There was  a significant difference
in the improvement from baseline to post-test between the three
anxiety disorders on the BAI (p = 0.01), but not on the HAMA, the
STAI-Trait and STAI-State. The improvement in patients with panic
disorder was  higher than in those with GAD or SAD, and there was
no difference between SAD and GAD.
3.7. Generic and disorder-specific outcome instruments
In order to examine whether the effect sizes found for the
generic anxiety measures (BAI, HAMA and STAI) differed from the
disorder-specific outcomes, we calculated the pooled effect sizes
for the disorder-specific outcomes (Table 3), as well as the effect
size based on the disorder-specific instruments for each disorder
that were reported in at least five studies (the PSWQ for GAD,
SIAS for SAD, and number of panic attacks for panic). Four stud-
ies did not present data on disorder-specific outcome measures
and were excluded from these analyses. As can be seen in Table 3,
the outcomes for the disorder-specific instruments did not deviate
considerably from the generic anxiety measures, and also indicated
larger effects for panic disorder than for GAD and SAD. Because
the generic and disorder-specific effect sizes came from the same
studies, we could not directly compare them and test whether the
differences between them were significant.
3.8. Multivariate metaregression analyses
We  conducted a multivarate metaregression analysis with the
effect size based on the BAI as dependent variable. As predictors we
entered type of disorder (GAD, SAD or panic disorder), the baseline
score on the BAI, and other main characteristics of the studies. The
results are presented in Table 5. As can be seen, type of disorder
remained a significant predictor of outcome, while adjusting for
the other characteristics of the studies. We  then conducted a man-
ual back-step metaregression analysis. In this analysis, we dropped
the least significant variable in each step, until only significant pre-
dictors were retained in the model (Table 5). The results of this
parsimonious model indicated that type of disorder was still sig-
nificantly associated with the effect size and was in fact the only
significant predictor.
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Table  3
Relative effects of cognitive and behavioral therapies for GAD, SAD and panic disorder on general measures of anxiety: Hedges’ g and Mean Difference.a
Ncomp g 95% CI MD 95% CI I2 95% CI pb NNT
Beck Anxiety Inventory
–Generalized anxiety disorder 9 0.73 0.48–0.98 6.06 3.96–8.16 0 0–54 0.001 2.54
–Social anxiety disorder 8 0.73 0.56–0.90 5.92 4.64–7.20 46 0–74 2.54
–Panic disorder 4 1.48 1.13–1.83 13.33 10.58–16.07 0 0–68 1.42
Hamilton
–Generalized anxiety disorder 11 0.98 0.70–1.26 6.47 4.90–8.05 46 0–72 0.85 1.95
–Social anxiety disorder 2 1.35 0.88–1.81 7.04 5.10–8.99 22 c 1.52
–Panic disorder 11 0.95 0.57–1.33 7.28 4.23–10.34 73 45–84 2.01
STAI-State
–Generalized anxiety disorder 5 0.55 0.28–0.81 6.75 3.53–9.98 0 0–64 0.64 3.31
–Social anxiety disorder 3 0.79 0.35–1.23 7.49 3.35–11.62 0 0–73 2.36
–Panic disorder 2 0.62 −1.16–2.40 8.80 −13.55–31.16 91 c 2.96
STAI-Trait
–Generalized anxiety disorder 16 0.50 0.37–0.64 5.46 4.04–6.88 0 0–45 0.86 3.62
–Social anxiety disorder 2 0.65 −0.55–1.84 7.11 −5.57–19.79 77 c 2.82
–Panic disorder 5 0.30 −0.50–1.09 3.41 −2.65–9.47 85 59–92 5.95
All  disorder-specific outcomes
–Generalized anxiety disorder 22 0.64 0.49–0.78 d 24 0–54 0.006 2.86
–Social anxiety disorder 13 1.01 0.70–1.31 66 28–80 1.91
–Panic disorder 16 1.16 0.81–1.51 75 55–83 1.70
Disorder-specific outcomes
–GAD: PSWQ 13 0.73 0.47–0.99 64 23–79 2.54
–SAD:  SIAS 7 0.80 0.21–1.38 84 64–90 2.34
–Panic: attacks/(2) wks 5 2.10 0.69–3.50 93 87–95 1.16
Abbreviations: CI: Confidence interval; MD:  mean difference (not standardized); Ncomp: number of comparisons; NNT: Numbers-needed-to-treat.
a According to the random effects model.
b The p-values in this column indicate whether the difference between the effect sizes in the subgroups is significant.
c The 95% CI of I2 cannot be calculated when the number of studies is two or smaller.
d The mean difference can not be calculated when outcomes from different measurement instruments are pooled.
    g 95 % CI  p  g (95% CI) 
GAD   Bakh shani, 2007  1.13  0.03 ~2.24   0.04 
Butl er,  199 1 bt  0.52  -0.13~1.16   0.12 
Butl er,  199 1 cbt  0.99  0.32 ~1.65   0.00 
Dugas,  2003   1.03  0.46~1.60   0.00 
Ladouc eur, 2000  0.79  0.01 ~1.57   0.05 
Mohlman, 2003a 0.19 -0.64~1.01 0.65 
Stanley, 2003b 0.95 -0.30~2.20 0.13 
Wetherell,  2003   0.59  -0.0 4~1.22   0.07 
Zinbarg, 2007   0.37  -0.5 2~1.27   0.41 
Pooled 0.73  0.48 ~0.98   0.00 
Panic  Ca rlbr ing,  2001   1.19  0.53~1.84   0.00 
Carlbring,  2006   1.37  0.81~1.92   0.00 
Clark, 1999 brief cbt  1.84  0.98 ~2.71   0.00 
Clark, 1999 full  cb t  1.89  1.01 ~2.76   0.00 
Pooled   1.48  1.13 ~1.82   0.00 
SAD   Anderss on, 2006  0.58  0.08 ~1.07   0.02 
Anderss on, 2012 a  0.61  0.33 ~0.89   0.00 
Carlbr ing,  2007   0.82  0.29~1.36   0.00 
Clark, 2006 ct 1.78 1.07~2.50 0.00 
Clark, 2006 exp+a r  0.94  0.30 ~1.57  0.00 
Himle,  2014   0.95  0.42 ~1.49   0.00 
Stang ier,  2003 Grp  0.28  -0.31~0 .87  0.36 
Stangier, 2003 Ind 0.62 0.02~1.23 0.04 











Overall Pooled 0.90 0.74~
Fig. 2. Forrest plot of effects sizes according to the BAI in randomized controll
. Discussion
We  wanted to examine whether the effects of cognitive and
ehavioral psychotherapies on generic anxiety measures differed
cross three of the most prevalent anxiety disorders: general-
zed anxiety disorder, social anxiety disorder and panic disorder.
e  examined generic anxiety measures utilized across anxiety
isorders, because disorder-specific measures do not allow for
irect comparisons of the effects across disorders. We  found that
he effects as measured with the BAI on panic disorder were0.00 
0 00 1 00 2 00
ls in generalized anxiety disorder, social anxiety disorder and panic disorder.
significantly larger than those on GAD and SAD, and we found
no significant difference between SAD and GAD. The difference
between the effects on panic disorder on the one hand, and GAD and
SAD on the other remained significant after adjusting for baseline
severity and other major characteristics of the trials. These find-
ings are in line with earlier meta-analyses using disorder-specific
outcomes, indicating large effects for treatments of panic disorder
(Sánchez-Meca et al., 2010) and somewhat smaller effects for GAD
(Cuijpers, Sijbrandij et al., 2014) and SAD (Eskildsen et al., 2010).
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Table  4
Improvement from baseline to post-test in cognitive and behavioral therapies for GAD, SAD and panic disorder on general measures of anxiety: Hedges’ g and Mean Difference.a
Ncomp g 95% CI MD 95% CI I2 95% CI pb
Beck Anxiety Inventory
–Generalized anxiety disorder 9 0.80 0.53–1.06 8.65 7.29–10.01 67 16–82 0.01
–Social anxiety disorder 8 0.81 0.58–1.03 6.91 6.18–7.64 77 45–87
–Panic  disorder 4 1.37 1.14–1.61 13.40 11.88–14.92 51 0–82
Hamilton
–Generalized anxiety disorder 11 1.34 0.99–1.69 8.36 6.17–10.54 84 72–89 0.85
–Social  anxiety disorder 2 1.41 1.17–1.66 9.99 8.87–11.11 15 c
–Panic disorder 10 1.30 0.96–1.64 9.26 6.85–11.68 83 70–89
STAI-State
–Generalized anxiety disorder 5 0.95 0.65–1.25 11.90 8.65–15.15 76 11–88 0.38
–Social  anxiety disorder 3 0.70 0.49–0.90 8.54 5.57–11.50 0 0–73
–Panic  disorder 2 0.74 0.35–1.13 9.75 1.51–17.99 46 c
STAI-Trait
–Generalized anxiety disorder 16 0.67 0.50–0.85 7.35 5.41–9.29 80 68–87 0.38
–Social  anxiety disorder 2 0.57 0.27–0.87 7.49 3.89–11.09 0 c
–Panic disorder 5 0.38 −0.02–0.77 3.87 −0.18–7.93 82 45–90
Abbreviations: CI: Confidence interval; MD:  mean difference (not standardized); Ncomp: number of comparisons.
a According to the random effects model.
b The p-values in this column indicate whether the difference between the effect sizes in the subgroups is significant.
c The 95% CI of I2 cannot be calculated when the number of studies is two or smaller.
Table 5
Standardized regression coefficients of characteristics of studies on cognitive behavior therapy on anxiety disorders with the Beck Anxiety Inventory as outcome measure:
Multivariate regression analysis.
Predictor Full model Parsimonious model
Coeff. 95% CI p Coeff. 95% CI p
Disorder –GAD Ref. 0.02 Ref. 0.01
–Panic 1.17 0.33–2.00 0.76 0.27–1.25
–SAD 0.08 −0.59–0.76 0.02 −0.34–0.37
Baseline score 0.00 −0.07–0.07 0.95
Recruitment –Clinical Ref. 0.46
–Community −0.25 −1.21–0.71
–Other −0.72 −2.06–0.61
Specific target group (yes/no; dummy) −0.22 −1.04–0.59 0.55
Control group –Waiting list −0.95 −2.07–0.18 0.09
Treatment format –Individual Ref. 0.66
–Group 0.28 −0.43–0.99
–Guided self-help −0.11 −1.01–0.80
–Other/mixed −0.14 −1.06–0.78
Number of sessions 0.09 −0.03–0.20 0.12



















bbreviations: CI: Confidence interval; Coeff.: Standardized regression coefficient; 
Our findings suggest that treatment of panic disorder may  result
n better outcomes than treatment of GAD and SAD. However, this
uggestion should be considered with caution because this differ-
nce was only found for the BAI and not for other generic outcomes.
lso, the quality of the included studies was not optimal and risk of
ias was considerable in most studies. And finally, the number of
tudies in panic disorders was small and the risk of a chance finding
onsiderable. On the other hand the difference between panic dis-
rder and the other disorders was large and remained significant
fter adjusting for major characteristics of the studies.
We also compared the effect sizes found for generic outcomes
ith those of disorder-specific outcome measures and found no
ajor differences between these two categories. This suggests that
here are no major differences between the two types of outcome
nstruments, although this finding has to be considered with cau-
ion because a direct comparison between the two  categories was
ot possible..04 0.77 0.73 0.44–1.01 < 0.001
Generalized Anxiety Disorder; Panic: Panic Disorder; SAD: Social Anxiety Disorder.
All three anxiety disorders that were examined in this meta-
analysis seem to result in high effect sizes, regardless of whether
these were disorder-specific or generic anxiety outcomes. NNTs
between 2 and 3 were found for most outcomes and for panic a NNT
of less than 1.5 was found, which suggests that treatments of panic
are even more effective than treatments of GAD and SAD. That is
in line with earlier meta-analyses (Sánchez-Meca et al., 2010), and
still good news for patients and clinicians. Furthermore, it suggests
that at a population level, the disease burden of anxiety disorders
can be reduced considerably with existing treatments and that is
even more likely for panic disorders.
The reasons why panic disorder may  be more treatable than the
other included anxiety disorders is not clear. It may be possible
that general levels of anxiety are more affected when the number
of panic attacks is reduced after treatment than when more generic
problems like worry or anxiety in social situations are reduced, but
this remains a matter of speculation. It is also possible that the
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*Carter, M. M.,  Sbrocco, T., Gore, K. L., Marin, N. W.,  & Lewis, E. L. (2003).P. Cuijpers et al. / Journal of A
ents are better. It was not possible to examine this in more detail,
owever, because the components in the studies differed consid-
rably and it was not possible to make more specific categories of
herapies in this analysis.
The reason that this difference was found for the BAI, but not
or other generic measures of anxiety also remains unclear. The
AI was developed specifically to measure anxiety so that it was
ifferentiated from depression and this was not the case for the
ther measures. It is also a self-report measure, unlike the HAMA,
hich was also used in a large number of the studies included. The
TAI measures are also self-report, though it is worth noting that
he number of studies using the STAI was small. It is also possible
hat the BAI is more sensitive to panic symptoms, with one study
uggesting that this scale appears to actually measure panic attacks
ather than anxiety in general (Cox, Cohen, Direnfeld, & Swinson,
996). However, another factorial analysis concluded that as a
easure of treatment-related changes, the BAI was more related
o general anxiety than to panic symptoms (de Beurs, Wilson,
hambless, Goldstein, & Feske, 1997).
This study found that all three anxiety disorders can be treated
ffectively in many patients, and that panic disorder may  be treated
ven more effectively than the other two disorders. However, this
s only based on comparing the effects of treatments on generic
nxiety measures. Future research is needed to assess the rela-
ive outcomes of treatments on other important outcomes that
re not directly related to anxiety, like quality of life, functional
imitations and functioning in daily life. Such measures may  give
 more comprehensive overview of the outcomes of treatments
n the disease burden of anxiety disorders. More research is also
eeded to improve the effects of treatments, especially for GAD and
AD, because even if the effects of treatments are generally positive,
here is still a considerable number of patients that do not benefit.
urthermore, this meta-analysis focused on short-term outcomes,
hile long-term outcomes are more important for patients, clin-
cians and the burdenof disorders from a public health point of
iew.
This study has several important limitations that should be con-
idered. Several of these have been mentioned already, including
he small number of studies in several subgroups, the high risk of
ias in most studies, differences between therapies that could not
e categorized, and the fact that all outcomes may  not be captured
y measures that are not disorder-specific. To these we add that
hese analyses were only conducted for outcomes at post-test and
ong-term effects were not considered.
Despite these limitations, it is interesting to note that cognitive
nd behavioral therapies may  have a different impact on anxi-
ty and the disease burden in patients. Although more research
s needed to verify whether this is indeed true, such differential
ffects of treatments across disorders may  be helpful in design-
ng optimal strategies for reducing the disease burden of anxiety
isorders.
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